Mu Dan Pi Paeonol.

Moutan bark is one of the three draining herbs balancing rehmannia in the six-ingredient base formula, and the two are dosed in a fixed ratio in every version of it.

In the six-ingredient base each tonifying herb is matched to a draining one, and moutan bark is the specific counterweight paired with cornus.

Moutan bark and gardenia are the two herbs added together to make the cooling variant of the classic harmonising formula, which is named after the pair.

Moutan bark and di gu pi are the standard couplet for night-time warmth, one cooling from the blood layer and the other from the interior.

Paeonol damps normal platelet aggregation and thromboxane formation, and long-chain omega-3 fatty acids shift the same eicosanoid balance, so the two add up at the platelet.

Ginkgolides block platelet-activating factor while paeonol reduces thromboxane-driven aggregation, so their effects on normal clotting are additive.

Garlic thiosulfinates and paeonol both damp normal platelet aggregation through separate routes, so stacking them compounds the effect.

Salicin from willow is metabolised to salicylic acid, which inhibits cyclooxygenase and reduces platelet thromboxane production. Paeonol has documented antiplatelet and eicosanoid-modulating activity in preclinical work. Combined, the effect on bleeding tendency adds, and that is the practical point to flag rather than a shared benefit.

Nattokinase acts on fibrin and clot dynamics while paeonol has been shown in laboratory and animal work to inhibit platelet aggregation. Stacking the two compounds the effect on bleeding tendency. This deserves flagging before any procedure and for anyone whose clotting is being managed clinically.

Gingerols inhibit thromboxane synthesis, the same broad target paeonol has been described as acting on. Their platelet effects therefore add rather than complement. Both also turn up in warming, circulation-oriented traditional formulas, which makes the combination common and the flag worth stating plainly.

Bromelain has described effects on platelet aggregation and fibrinolysis, overlapping with paeonol's preclinical antiplatelet activity. The combined effect on bleeding tendency is additive. Evidence for each piece is laboratory-level, which is where the promising label comes from.

Both are phenolic compounds described as reducing production of inflammatory mediators, curcumin largely through NF-kB and related signalling and paeonol through cyclooxygenase-linked and cytokine pathways in preclinical models. Both are also poorly water soluble and heavily conjugated after oral dosing, so they share a bioavailability problem as well as a target. Curcumin also has a mild platelet effect, so the bleeding note applies.

Boswellic acids inhibit 5-lipoxygenase and so the leukotriene branch, while paeonol's described activity sits nearer the cyclooxygenase and cytokine side. Hitting two branches of eicosanoid production is the rationale for combining them. Both are lipophilic and benefit from being taken with fat, which is a practical point as much as a chemical one.

Quercetin inhibits UDP-glucuronosyltransferase and sulfotransferase activity, the same conjugation route that clears paeonol rapidly after an oral dose. Slowing that clearance would raise paeonol exposure, which is a pharmacokinetic interaction rather than a benefit in itself. Quercetin also has its own antiplatelet activity, adding to paeonol's.

Piperine inhibits glucuronidation and several CYP enzymes, which is why it raises the plasma exposure of a number of poorly bioavailable phenolics. Paeonol is cleared largely by glucuronidation and sulfation, so the same mechanism plausibly applies to it. Higher exposure is not automatically better and it changes the dose relationship, so this is listed as a modifier.

Paeonol is a lipophilic, poorly water-soluble phenolic ketone. Complexing such compounds with phospholipids, the phytosome approach used for silymarin and curcumin, is the standard way to improve their dispersion and absorption. The delivery principle is well established even where the specific paeonol data is not.

A lipid carrier keeps a poorly water-soluble phenolic in solution and recruits the fat digestion and micelle pathway rather than leaving it to dissolve in gastric fluid. This is why lipophilic extracts are conventionally taken with a fat-containing meal. It changes delivery, not the molecule.

Silymarin flavonolignans compete for the same glucuronidation capacity that clears paeonol, so co-dosing can shift the exposure of both. They are also both classic phytosome candidates for the same solubility reason. The interaction described is on handling and clearance, not on a shared effect.

Licorice is the classical harmonising herb added across a great many traditional formulas, including those built around Moutan cortex, and its role in that framework is to moderate and integrate the other ingredients. Pharmacologically, glycyrrhizin carries its own mineralocorticoid-like effect on potassium and blood pressure at sustained intake, which is a real consideration independent of the traditional role. Both facts belong on the row.

Angelica sinensis is the other principal blood-moving material paired with Moutan cortex in classical formulas. Both also carry coumarin-type and phenolic constituents with described effects on platelet function, so the traditional pairing and the modern platelet flag point the same way. Additive effect on bleeding tendency is the note.

Moutan cortex carries gallotannins and gallic acid, and polyphenols of that class bind non-heme iron in the gut lumen to form poorly absorbed complexes. An iron dose taken with a tannin-rich decoction is therefore less well absorbed. Separating the two by a couple of hours is the standard answer.

Ascorbate partly counteracts tannin inhibition of non-heme iron absorption by keeping iron reduced and soluble, so it changes the mineral arithmetic of a tannin-rich preparation. It also participates in the same redox network as the extract's phenolics. Two distinct interactions, both on handling rather than on any effect of paeonol itself.

Paeonol is a phenolic antioxidant that partitions into lipid environments, the same compartment alpha-tocopherol protects, and phenolic antioxidants in that phase can spare one another. The relationship is described in lipid oxidation chemistry rather than in human outcome trials. Additive protection of membrane lipids is the claim, and it is a chemical one.

Both are small lipophilic phenolics cleared rapidly by glucuronidation and sulfation, and both are described in preclinical work as acting on the same inflammatory signalling nodes. That means an overlapping target and competition for the same conjugation capacity. The preclinical overlap is real; the human data for either at ordinary doses is limited.